Provided by Tiger Trade Technology Pte. Ltd.

Seer, Inc.

1.79
-0.0300-1.65%
Post-market: 1.880.0900+5.03%19:16 EST
Volume:287.54K
Turnover:517.86K
Market Cap:99.86M
PE:-1.31
High:1.84
Open:1.81
Low:1.77
Close:1.82
52wk High:2.50
52wk Low:1.62
Shares:55.79M
Float Shares:39.55M
Volume Ratio:1.44
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3630
EPS(LYR):-1.3890
ROE:-25.74%
ROA:-15.19%
PB:0.37
PE(LYR):-1.29

Loading ...

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

prnewswire
·
Dec 08

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

GlobeNewswire
·
Dec 01

Seer, Inc. Earnings Call: Achievements Amid Challenges

TIPRANKS
·
Nov 08

Seer Inc. Showcases Deep Proteomics Advances at HUPO World Congress

Reuters
·
Nov 07

Life sciences company Seer's Q3 net loss narrows

Reuters
·
Nov 07

Seer Q3 EPS USD -0.32

Reuters
·
Nov 07

Seer Q3 EPS $(0.32) Misses $(0.31) Estimate, Sales $4.121M Beat $4.000M Estimate

Benzinga
·
Nov 07

Seer Inc. reports Q3 revenue of $4.1 million

Reuters
·
Nov 07

Seer Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 07

Seer Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
Nov 05

Seer Inc. to Participate in UBS Global Healthcare Conference

Reuters
·
Oct 30

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Oct 17

RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases

Reuters
·
Oct 16

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

GlobeNewswire
·
Oct 14

Seer Inc announces date for special stockholder meeting

Reuters
·
Oct 10

Seer Inc to Showcase Proteomics Advances at American Society of Human Genetics Annual Meeting

Reuters
·
Oct 10

Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer

prnewswire
·
Sep 12

Seer Inc. Appoints Isaac Ro to Board of Directors, Enhancing Leadership with Financial and Life Sciences Expertise

Reuters
·
Sep 06

Seer Inc. Files Initial Statement of Beneficial Ownership; Isaac Ro Named as Director

Reuters
·
Sep 04

Seer Appoints Isaac Ro to Its Board of Directors

THOMSON REUTERS
·
Sep 02